Females of childbearing potential must agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or agree to completely abstain from heterosexual intercourse
WOCBP must agree to follow instructions for method(s) of contraception from the time of signing consent and until  months after last dose of study therapy
If they are of childbearing potential, agree to practice  effective method of contraception and  additional effective (barrier) method, at the same time, from the time of signing the ICF through  days (or longer, as mandated by local labeling [e.g., United Surgical Partners International, summary of product characteristics, etc.] after the last dose of the study drugs, OR
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, OR
Women of childbearing potential must agree to follow instructions for acceptable contraception from the time of signing consent, and for  weeks after their last dose of protocol-indicated treatment.
Males or females of childbearing potential who do not agree to practice  effective methods of contraception, at the same time through  days after the last dose of study drug
If they are of childbearing potential, agree to practice  highly effective method of contraception and  additional effective (barrier) method at the same time, from the time of signing the informed consent through  days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc.]) after the last dose of study drug, OR
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study treatment, AND
If they are of childbearing potential, agree to practice  highly effective method of contraception, and  additional effective (barrier) method, at the same time, from the time of signing the informed consent through  days (or longer, as mandated by local labeling [example, United States Prescribing Information (USPI), Summary of Product Characteristics (SmPC), etc;]) after the last dose of study drug, OR
If they are of childbearing potential, agree to practice  highly effective method and  additional effective (barrier) method of contraception at the same time, from the time of signing the informed consent through  months after the last dose of study drug, or
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  months after the last dose of study drug, OR
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, AND
Female participants who are postmenopausal for at least  year before the screening visit or are surgically sterile, or are of childbearing potential, agree to practice  highly effective method and  additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through  days (or longer, as mandated by local labeling) after the last dose of study drug, or agree to practice true abstinence.
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or
If they are of childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through four months after the last dose of study drug, or
If they are of childbearing potential, agree to practice  highly effective method of contraception and  additional effective (barrier) method at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or
Both men and women in the rituximab combination arm (Cohort B) must practice contraception as described above from the time of signing of the informed consent form (ICF) through  months after the last dose of study drug.
Female patients of childbearing potential or less than  years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until  days after study completion
For study Arm , female subjects of childbearing potential or less than  years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until  days after study completion unless total hysterectomy performed at the time of original operation
Female patients of childbearing potential or less than  years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until  days after study completion
If childbearing potential, agree to practice  effective methods of contraception, at the same time, from the time of signing the informed consent through  days after the last dose of study drug, or